Related Experiment Video

Updated: Aug 7, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis

Yi Zhao1, Suofu Qin, Larissa I Atangan

  • 1Retinoid Research, Department of Biology, Allergan Inc., Irvine, California 92612, USA. zhao_yi@allergan.com

The Journal of Biological Chemistry
|May 8, 2004
PubMed

Insights

Retinoid X receptor (RXR) agonists show anti-cancer potential, but mechanisms are unclear. This study reveals casein kinase 1alpha (CK1alpha) inhibits RXR agonist-induced apoptosis, suggesting CK1alpha inhibition could enhance cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Retinoid X receptor (RXR) agonists, including 9-cis-retinoic acid, induce cancer cell growth arrest and apoptosis.
  • RXR agonists are investigated for solid tumor treatment and used for cutaneous T-cell lymphoma.
  • The precise molecular mechanisms behind RXR agonists' anti-cancer effects are not fully understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying the anti-cancer effects of RXR agonists.
  • To identify novel regulators of RXR agonist-induced apoptosis.
  • To explore the role of casein kinase 1alpha (CK1alpha) in RXR signaling.

Main Methods:

  • Investigated the interaction between RXR and CK1alpha in cancer cells treated with RXR agonists.
  • Assessed the phosphorylation of RXR by CK1alpha.
  • Correlated CK1alpha-RXR complex formation with growth inhibition.
  • Examined the effects of CK1alpha depletion on cancer cell sensitivity to RXR agonists.

Main Results:

  • A novel pro-apoptotic pathway induced by RXR agonists is negatively regulated by CK1alpha.
  • CK1alpha associates with RXR in an agonist-dependent manner and phosphorylates RXR.
  • The recruitment of CK1alpha to RXR inversely correlates with the agonist's growth inhibitory potency.
  • Depleting CK1alpha restores sensitivity to RXR agonist-induced growth inhibition and apoptosis in resistant cells.

Conclusions:

  • CK1alpha promotes cancer cell survival by hindering RXR agonist-induced apoptosis.
  • Inhibition of CK1alpha represents a potential strategy to potentiate the anti-cancer efficacy of RXR agonists.
  • Targeting the CK1alpha-RXR interaction could offer new therapeutic avenues in cancer treatment.

More Related Videos

Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation09:07

Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation

Published on: June 21, 2016

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...